Lead Product(s): AK-OTOF
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pivotal bioVenture Partners
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 03, 2020
Proceeds will be used to advance Akouos’s lead program, AK-OTOF, to first-in-human clinical studies subject to IND filing and to establish the company’s in-house GMP manufacturing capabilities.